Abstract Cannabis has been around for thousands of years and has been used recreationally, medicinally, and for fiber. Over 500 compounds have been isolated from Cannabis sativa with approximately 105 being cannabinoids. Of those 105 compounds, D 9
Introduction
Marijuana, also known as Cannabis, is defined as any preparation of the Cannabis plant used to elicit psychoactive effects whether it is recreational or medicinal. According to the 2004 World Drug Report, 3.7 % of the population 15-64 years of age consumed marijuana from 2001 (2004 2010 World Drug Report) . The use of marijuana is associated with numerous pharmacological effects; most, but not all may be attributed to D 9 -tetrahydrocannabinol (D 9 -THC) (Gaoni and Mechoulam, 1964) . The combination of D 9 -THC and other compounds from Cannabis, such as cannabidiol (CBD), may exhibit specific pharmacological effects. Since D 9 -THC is primarily responsible for the psychoactive effects of Cannabis, scientists have learned how to genetically increase the concentration of D 9 -THC within plants to produce a higher percentage (ElSohly, 2000) . Since 1993, the concentration of D 9 -THC within marijuana has increased from 3.4 % to approximately 8.8 % in 2008 (Mehmedic et al., 2010) .
Cannabis use has been reported for thousands of years and is not only associated with recreational or medicinal use, but it is also used for fiber and seeds. Cannabis produces a durable fiber, called hemp, for the manufacturing of rope and fabric. Along with the production of hemp, the seeds of Cannabis are rich in unsaturated fatty acids. The use of Cannabis dates back to around 2000 BC when the Chinese invented hemp paper (Peters and Nahas, 1999) . In Dr. Mahmoud ElSohly's book published in 2010, Marijuana and the Cannabinoids, it is noted that Cannabis serves as a recreational drug and, more importantly, as a potential therapeutic treatment for numerous diseases such as wasting syndrome, obesity, and multiple sclerosis (Clarke and Watson, 2010) .
The CB1 receptor is encoded by the CNR1 gene, and is widely expressed throughout the brain. It is also expressed in the spinal cord, pituitary gland, thyroid gland, adrenal gland, fat cells, muscle cells, liver cells, digestive tract, lungs, kidneys, and male and female reproductive organs. Gerrard et al. (1991) cloned the rat cannabinoid receptor; shortly after, isolation of a human CB1 receptor cDNA was reported. The amino acid sequence showed 472 total amino acids, one less than other mammalian species (Matsuda, 1991) . This receptor has been the target of much research due to the pharmacological effects associated with its activation (Pertwee, 1997) .
Shortly after characterizing and cloning the human CB1 receptor, the CB2 receptor was cloned (Devane, 1992) . The CNR2 gene encodes the CB2 receptor, and the amino acid sequence shows approximately 360 total amino acids. The CB1 and CB2 receptors have approximately 44 % similarity of their amino acid sequences (Munro et al., 1993) . The CB2 receptors are widely expressed throughout the peripheral tissues of the immune system, spleen, tonsils, thymus, and gastrointestinal system. Further investigation of CB2 receptors led to the discovery that these receptors are also expressed within the brain (Onaivi et al., 2006) . The CB2 receptors play a major role in inflammatory diseases due to their interaction with these receptors in the immune system (Cabral and Griffin-Thomas, 2009 ).
This misuse of Cannabis negatively affects the people who need help with unwanted side effects associated with cancer chemotherapy and AIDS. Cannabis is not only used to help those suffering from cancer chemotherapy and AIDS (Harrigan, 2001) (Berry and Mechoulam, 2002) , but it also lowers intraocular pressure for those with glaucoma, acts as a pain reliever, and more recently has been found to help with symptoms of multiple sclerosis, Alzheimer's, and depression (Benito, 2003) . Therefore, researchers are attempting to formulate synthetic cannabinoids that resemble the compounds isolated from Cannabis, but do not express psychotropic properties.
During the past century, and especially in the past 20 years, researchers have investigated D 9 -Tetrahydrocannabinol (THC), the primary active constituent in marijuana, and it derivatives, for medical uses (Ahmed et al., 2008; Ross et al., 2005) . These uses include wasting-syndrome in AIDS patients, anti-anxiety, antiemetic (in patients receiving cancer chemotherapy), analgetic (especially in cancer pain), anti-inflammatory, and neuroprotective effects, among others. The development of treatment strategies for these disorders remains a high priority. The broad effects associated with THC and other cannabinoids are directly related to the endocannabinoid system, which is a major regulatory system of the central and peripheral nervous system. The endocannabinoid system, composed of cannabinoid receptors (CB1 and CB2), their endogenous ligands, and the enzymes responsible for metabolizing these ligands, is linked to the control of various physiological processes. These include depression, anxiety, and drug addiction, among others, and it is clear that the endocannabinoid system provides a valuable new therapeutic target for a variety of disorders (Lambert, 2009) .
Though much effort has been exerted in discovering and developing cannabinoid receptor ligands, there are still few marketed drugs in this category, and hence there is great potential and urgency for application of rational drug design for discovery of novel cannabinoid ligands. This study will help scientist gain a better understanding of the structure-activity relationship (SAR) of ligands binding affinity for these receptors.
Materials and methods

Plant material
Cannabis sativa plants were grown from high-potency Mexican seeds. The seeds and plants were authenticated by Dr. Suman Chandra, University of Mississippi, and a specimen (S1310V1) was deposited at the Coy Waller Complex, National Center for Natural Products Research, School of Pharmacy, University of Mississippi. Whole buds of mature female plants were harvested, air-dried, and packed in barrels; and stored at -24°C.
Cell culture
Parental HEK293 cells were stably transfected via electroporation with full-length human recombinant cDNA for cannabinoid receptor subtypes 1 and 2. The human recombinant cDNA was obtained from Origene. Once transfected, the cells were maintained at 37°C and 5 % CO 2 in a Dulbecco's Modified Eagle's medium (DMEM) nutrient mixture F-12 HAM supplemented with 2 mM L-glutamine, 10 % fetal bovine serum (FBS), 0.5 % penicillin-streptomycin, and G418 (Geneticin, 600 mg/ mL). A single cell was picked from the parental plate and forced to replicate on its own in a fresh plate with the appropriate media. Membranes were prepared by scraping the cells in a 50 mM Tris-HCl buffer, homogenized via sonication, and centrifuged for 40 min at 13,650 rpm at 4°C. The membranes were stored at -80°C. Protein concentrations for each membrane preparation were found using the Bradford protein assay.
Competitive binding assay
The binding assays were performed using slight modifications to previously published methods (Pertwee, 1999) . Using 0.5 nM 3 H-CP-55940, 10 lM test compound (unless dose-response then first well is 100 lM followed by appropriate dilutions), and 10 lg protein of membrane for a total assay volume of 210 lL. Binding was initiated by the addition of 10 lg protein of CB1 or CB2 cell membranes. Assays were carried out at 37°C for 90 min before termination via rapid vacuum filtration through Whatman GF/C glass-fiber filters, presoaked with 0.3 % BSA, using a Perkin Elmer 96-well Unifilter Harvester (Perkin Elmer Life Sciences Inc., Boston, MA, U.S.A.). Each assay plate was washed seven times with ice-cold wash buffer (50 mM Tris, 154 mM NaCl, 20 mM disodium ethylenediaminetetraacetic acid (EDTA), 0.2 % BSA, and pH = 7.4). Filters were allowed to dry overnight at room temperature (25°C) and then radioactive counts were extracted from the filters using a scintillation cocktail before quantification using a Perkin Elmer TopCount (Perking Elmer Life Sciences Inc., Boston, Mass. U.S.A). There results were calculated using GraphPad Prism (GraphPad Software, San Diego, CA, U.S.A.) to obtain K i and IC 50 values. Total binding was defined as binding in the presence of 0.1 % dimethylsulfoxide (DMSO). Non-specific binding was the binding observed in the presence of 0.1 lM CP-55940. Specific binding was defined as the difference between total and non-specific binding.
GTPcS functional assay
The functional assays were performed using slight modifications to previously published methods (Xiong et al., 2011) . The assay buffer for the GTPcS functional assay consisted of 50 mM Tris-HCl, 0.2 mM ethylene glycol tetraacetic acid (EGTA), 9 mM MgCl 2 , 150 mM NaCl, and 1.4 g BSA. Binding took place under the following conditions: 50 lL compound diluted to the desired concentrations in the dose-response curve was mixed with 20 lg CB1 or CB2 membrane, 50 lM GDP, 0.5 nM 35 S-labeled GTP, and 300 lL assay buffer for a total volume of 500 lL per well. Plates were incubated for 120 min at 37°C. The reaction was terminated via rapid vacuum filtration through Whatman GF/B filters using a Perkin Elmer 96-well Unifilter Harvester (Perkin Elmer Life Sciences Inc., Boston, MA, U.S.A.). Each assay plate was washed four times with ice-cold wash buffer (10 mM Tris-HCl, pH 7.4). Filter plates were allowed to dry overnight at room temperature (25°C) and then radioactive counts were extracted from the filters using a scintillation cocktail before quantification using a Perkin Elmer TopCount (Perking Elmer Life Sciences Inc., Boston, Mass. U.S.A). Basal binding was defined as binding in the presence of assay buffer. Nonspecific binding was the binding observed in the presence of 40 lM unlabeled GTPcS salt. Emax binding was defined as binding in the presence of 1 lM CP-55940. K i and EC 50 values were calculated using Graph Pad Prism (GraphPad Software, San Diego, CA, U.S.A.).
Results
The importance of developing a structure-activity relationship for the cannabinoid receptors is due to the lack of understanding of the receptor binding sites. Developing in vitro bioassays to evaluate binding affinity and functional activity for each of the cannabinoid receptors is critical to understanding the pharmacology behind these receptors. Currently, there is no crystal structure that exists for the cannabinoid receptors active binding site. This structure-activity relationship of phytocannabinoids may help further understand the pharmacology of these receptors along with requirements for their binding (Fig. 1) .
In most cases, if a ligand binds to a receptor then it would also functionally activate the receptor; however, this is not always true. Although compounds may bind tightly to a specific receptor, they do not always produce a biological response. It is not uncommon for GPCRs to dissociate upon binding of a ligand (Carlsson, 2010) . Conversely, some ligands may not bind to the specific receptor yet cause a functional response. This is thought to be because of an allosteric binding site, a binding site other than the two known cannabinoid receptors, in which the ligand still produces a functional effect via the endocannabinoid system pathway.
Binding
The use of radiolabeled competitive binding assays is a common technique for evaluating compounds and their binding affinities to specific receptors (Table 1) . D 9 -THC displayed binding affinity within the low nanomolar range for both CB1 and CB2 receptors, 18 and 42 nM, respectively. The isolated compounds within the D 9 -THC family all displayed weaker affinity for CB1 and CB2. D 8 -THC displays slightly lesser binding affinity than D 9 -THC for the CB1 receptor, suggesting that the location of the double bond has a role in binding affinity. Interestingly, 11 displayed strong binding affinity for the CB2 receptor with a Ki value of 11 nM. Therefore, substitutions at the C-8 position of cannabinol may have an influential effect on selectivity when binding to CB2. Compounds 12-23 did not warrant significant binding affinities.
Functional
Using radiolabeled functional bioassays allows for easily determining if a compound is acting as an agonist, partial agonist, antagonist, or inverse agonist. All phytocannabinoids mentioned in this study were determined to act as agonists using the GTPcS functional bioassay (Table 1) . Three compounds displayed single nanomolar activity for either CB1 or CB2 receptors. Cannabichromanone D (21) warranted an EC 50 of 8 nM for the CB1 receptor. This compound differs from the other compounds in the cannabichromanone class because the aliphatic chain cyclizes with the phenolic hydroxy to form a third ring. Though the cannabichromanone derivatives have not been evaluated for their ability to induce psychoactivity, it is safe to say that these compounds will induce psychoactivity, depending on the dose, because of their ability to functionally stimulate the CB1 receptor. However, cannabidivarin (23) displayed preferential activity for CB2 in the low nanomolar range, 3 nM. The importance of showing preference for the CB2 receptor is ideal in order to negate the side effects associated with activation of CB1, such as psychoactivity. Contrary to the side chain length associated with D 
Discussion
Cannabinoid receptors portray different pharmacological properties when activated by an agonist, antagonist, or inverse agonist. Agonists that stimulate CB1 cause some of the unwanted side effects associated with Cannabis, such as psychoactivity (Hensen, 2005) . Furthermore, inverse agonists that stimulate CB1 cause a loss of appetite, which in turn helps with the treatment of obesity. Rimonabant is an example of CB1-selective inverse agonist, and was marketed in Europe for the treatment of obesity until three years later when it was removed from the market. Removal of Rimonabant was due to those patients taking the drug having suicidal thoughts (Katoch-Rouse, 2003) . Since it was selective for CB1, it is hypothesized that stimulation of the CB1 receptor may be the link to causing any type of negative side effects associated with the endocannabinoid system, the system responsible for activating the cannabinoid receptors.
The results presented in this manuscript indicate that phytocannabinoids have the potential to become lead therapeutic compounds to help patients suffering from cancer chemotherapy, AIDS, multiple sclerosis, glaucoma, and several other major diseases, while negating unwanted side effects associated with CB1 stimulation. Some side effects associated with Cannabis use include, but are not limited to psychoactivity, dependence, and increased heart rate. This manuscript identifies and evaluates 23 isolates from Cannabis sativa. The effort to develop compounds useful for medication requires structural diversity in order to achieve therapeutic success. Using in vitro bioassays has led to two potential compounds that need further testing to determine pharmacological effects in vivo.
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